Mathematical modeling for antibody therapy in the setting of antigenic modulation.
The in vivo efficacy of passive monoclonal antibody therapy is limited in certain systems by the process of antigenic modulation. We describe a compartmental model which addresses the kinetics of in vivo cell binding of murine monoclonal antibody T101, modulation of the T65 target antigen, serum levels of T101, and elimination of target cells. Observed data compare favorably to that predicted by the model. The model suggests that there is no rationale for administering T101 as a prolonged, continuous infusion for passive antibody therapy.
Dillman
R O
RO
San Diego VA Medical Center, CA.
Koziol
J A
JA
Shawler
D L
DL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D008954:Models, Biological; D013601:T-Lymphocytes
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte